BCL2 and neoplasm: The mixture of LHRHPEG-siRNA (BCL2)-MSN and LHRH-PEG-siRNA (MRP1)-MSN provided effective downregulation of BCL2 and MRP1 mRNA levels in vitro, leading to tumor regression 132.